B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $10.5
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.
B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.